Khasraw M, Lassman AB. Advances in the treatment of malignant gliomas. Curr Oncol Rep, 2010, 12, 26-33.
Laperriere N, Weller M, Stupp R, et al. Optimal management of elderly patients with glioblastoma. Cancer Treat Rev, 2013, 39, 350-357.
Gorlia T, van den Bent MJ, Hegi ME, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol, 2008, 9, 29-38.
Earnest F, Kelly PJ, Scheithauer BW, et al. - Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology, 1988, 166, 823-827. (Pubitemid 18058950)
Stummer W, van den Bent MJ, Westphal M. Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies : new arguments in an old discussion. Acta Neurochir, 2011, 153, 1211-1218.
Lambert J. Evolution du traitement clinique des Glioblastomes : apports de la chimiothérapie par Temozolomide et de la chirurgie repétée. Mémoire présenté en vue de l'obtention du grade de master en sciences biomédicales, Université de Liège, 2011-2012.
Laperriere N, Zuraw L, Cairncross G. - Radiotherapy for newly diagnosed malignant glioma in adults : a systematic review. Radiother Oncol, 2002, 64, 259-273. (Pubitemid 35254019)
Tanaka M, Ino Y, Nakagawa K, et al. - High-dose conformal radiotherapy for supratentorial malignant glioma: a historical comparison. Lancet Oncol, 2005, 6, 953-960. (Pubitemid 41685228)
Wen PY, Macdonald D, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: Response assessment in Neuro-Oncology Working Group. J Clin Oncol, 2010, 28, 1963-1972.
Caroline I,Rosenthal MA. Imaging modalities in high-grade gliomas : pseudoprogression, recurrence, or necrosis? J Clin Neurosci, 2012, 19, 633-637.
Stupp R, Mason WP, van den Bent MJ, et al. - Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 2005 352, 987-996. (Pubitemid 40349501)
Lawrence YR, Blumenthal DT, Matceyevsky D, et al. Delayed initiation of radiotherapy for glioblastoma: how important is it to push to the front (or the back) of the line? J Neurooncol, 2011, 105, 1-7.
Arribas Alpuente L, Menendez Lopez A, Yaya Tur R, et al. Glioblastoma : changing expectations? Clin Transl Oncol, 2011, 13, 240-248.
Clavier JB, Voirin J, Kehrli P, et al. Systematic review of stereotactic radiotherapy for high-grade gliomas. Cancer Radiother, 2010, 14, 739-754.
Easaw JC, Mason WP, Perry J, et al. Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. Curr Oncol, 2011, 18, e126-e136.
Fine HA, Dear KB, Loeffler JS, et al. - Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer, 1993, 71, 2585-2597. (Pubitemid 23100496)
Stewart LA. - Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet, 2002, 359, 1011-1018. (Pubitemid 34286538)
Spiegel BM, Esrailian E, Laine L, et al. - Clinical impact of adjuvant chemotherapy in glioblastoma multiforme: a meta-analysis. CNS Drugs, 2007, 21, 775-787. (Pubitemid 47294722)
Ostermann S, Csajka C, Buclin T, et al. - Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res, 2004, 10, 3728-3736. (Pubitemid 38697606)
Stupp R, Hegi ME, Mason WP, et al. European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study : 5-year analysis of the EORTC-NCIC trial. Lancet Oncol, 2009, 10, 459-466.
Hegi ME, Diserens AC, Gorlia T, et al. - MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med, 2005, 352, 997-1003. (Pubitemid 40349502)
Braghiroli MI, Sabbaga J, Hoff PM. Bevacizumab: overview of the literature. Expert Rev Anticancer Ther, 2012, 12, 567-580.
Chinot OL, Wick W, Mason W, et al. Phase III trial of bevacizumab added to standard radiotherapy and temozolomide for newly-diagnosed glioblastoma : mature progression-free survival and preliminary overall survival results in AVAglio. NeuroOncology, 2012, 14, vi101-vi105.
Fink J, Born D, Chamberlain MC. Pseudoprogression : relevance with respect to treatment of high-grade gliomas. Curr Treat Options Oncol, 2011, 12, 240-252.
Sorensen AG, Batchelor TT, ZhangWT, et al. A"vascular normalization index"as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res, 2009, 69, 5296-5300.
